“ Breaking barriers, Restoring Minds”
We're dedicated to developing life-changing treatments for neurological disorders, with our first target set on demyelinating diseases.
Across Pharmaceuticals Inc. is building the next generation of targeted central nervous system (CNS) therapies by combining cutting-edge neurobiology with a validated blood-brain barrier (BBB) delivery platform. Our mission is to restore neurological function in patients suffering from diseases with high unmet needs in neuroinflammation and demyelinating disorders, such as multiple sclerosis, optic neuritis, and neurodegenerative disorders.
We have in-licensed the xB3 platform from Bioasis Technologies Inc., a proprietary BBB transport technology enabling efficient delivery of biologics into the brain. By integrating this platform with our Epidermal Growth Factor (EGF)-based regenerative approach, we are developing therapies that not only reach the CNS but actively promote repair and reduce inflammation. Our lead program — a novel EGF + xB3 combination — is designed to reverse demyelination and restore immune balance in progressive neurological diseases.
We are strategically focused on orphan and underserved CNS indications to accelerate clinical development and de-risk early value inflection points. With a clear path to IND-enabling studies and a differentiated mechanism of action, Across Pharmaceuticals Inc. offers a unique opportunity at the intersection of biologic innovation, targeted delivery, and therapeutic regeneration in neurology.
Epidermal Growth Factor (EGF) is a naturally occurring molecule essential to tissue development, repair, and regeneration — including in the central nervous system (CNS). In multiple preclinical studies, EGF has demonstrated a dual mechanism of action: it promotes the maturation of oligodendrocytes and stimulates myelin regeneration, while also reducing neuroinflammation by modulating macrophage polarization toward an anti-inflammatory phenotype.
Loss of EGF activity has been implicated in a number of neurodegenerative and demyelinating diseases, and restoring its presence may help reverse CNS damage. Its effects have been validated in models of multiple sclerosis, optic neuritis, Alzheimer’s, and Huntington’s disease, where EGF contributes to both structural recovery and improved clinical function.
Delivering large biologics like EGF into the brain has traditionally been limited by the blood-brain barrier (BBB) — one of the greatest challenges in neurology. Our proprietary xB3 platform, in-licensed from Bioasis Technologies Inc., solves this by enabling receptor- mediated transcytosis through the BBB via the LRP1 pathway, which is highly expressed on cerebral endothelial cells.
By combining xB3 with EGF, we create a targeted, disease-modifying therapy capable of reaching the site of neurological damage while minimizing peripheral side effects. This fusion approach enables effective CNS penetration, lower dosing, and the potential for broader application in neurodegenerative diseases that currently lack curative options.
The result is a novel therapeutic strategy that not only crosses the BBB but delivers a biologically active molecule with regenerative potential — offering new hope for patients facing progressive CNS disorders.
